
9.27 Delayed Data As of Jul 01 | ![]() Today’s Change | 4.31 Today|||52-Week Range 18.55 | -44.56% Year-to-Date |
SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $367.3M |
Kezar Life Sciences, Inc. 4000 Shoreline Court South San Francisco California 94080 |
John Fowler | Chief Executive Officer & Director |
Christopher J. Kirk | President, Director & Chief Scientific Officer |
Michael Wolfe | Director-Finance & Business Operations |
Marc L. Belsky | Chief Financial Officer & Secretary |
Noreen Roth Henig | Chief Medical Officer |